Form 4: Stoke Therapeutics Director Garry Menzel Granted Stock Options Valued at $10.9 Per Share

Stoke Therapeutics, Inc. Director Garry E. Menzel was granted 29,747 stock options with an exercise price of $10.9 per share, aligning his interests with shareholder value.

Summary

• Garry E. Menzel, a Director of Stoke Therapeutics, Inc. (STOK), was granted 29,747 Director Stock Options (Right to Buy) on June 3, 2025.
• The exercise price for these options is $10.9 per share.
• The options are set to vest in full on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, contingent upon Mr. Menzel's continued service to the company.
• The expiration date for these stock options is June 2, 2035.
• Following this transaction, Mr. Menzel directly beneficially owns 29,747 derivative securities.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (option grant) which is generally a neutral to slightly positive event as it aligns director interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of stock options to Director Garry E. Menzel aligns his financial interests with the long-term performance and shareholder value of Stoke Therapeutics, Inc.
• Equity compensation is a common practice to incentivize directors and retain talent.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, although this is a standard aspect of equity compensation plans.

Risks

• Potential future dilution of existing shares if the granted options are exercised, which is inherent in equity compensation plans.
• The value of the options is dependent on the future stock price performance of Stoke Therapeutics, Inc., which is subject to market and company-specific risks.

Future Outlook

The document indicates that the granted options will vest on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, subject to the director's continued service. This outlines the future timeline for the director's equity compensation.

Industry Context

The granting of stock options to directors is a standard practice across various industries, including biotechnology, to attract, retain, and incentivize experienced board members. This Form 4 filing reflects a routine compensation event for a director at Stoke Therapeutics, Inc., consistent with common corporate governance practices.

Comparison to Industry Standards

• The practice of granting stock options to directors is a widely accepted form of compensation in the biotechnology and pharmaceutical sectors, aligning director incentives with long-term company performance.
• While specific grant sizes vary based on company size, stage, and individual director roles, this grant size for a director at Stoke Therapeutics appears to be within typical ranges for similar-sized public companies in the industry, though without specific peer compensation data, a precise comparison is limited.

Corporate Governance

Related Party Transactions

• The grant of 29,747 stock options to Director Garry E. Menzel constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised in the future, but also benefits from increased alignment of director incentives with company performance.
• Director (Garry E. Menzel): Receives equity compensation, which ties his personal wealth to the company's stock performance, providing a direct incentive for value creation.

Next Steps

• The granted stock options will vest on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, provided the reporting person continues service.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership